Dynavax Technologies Corp. (DVAX), which reported a 10% rise in revenue for its lead product in the first quarter, expects revenue to increase 24% to 31% for full year 2024.
The lead product is HEPLISAV-B, indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. CpG 1018 is the adjuvant used in HEPLISAV-B to provide an increased vaccine immune response.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com